In the preemptive analgesia mode: a randomized controlled study of pregabalin combined with celecoxib in total knee arthroplasty

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100047594

Enrollment

Unknown

Registered

2021-06-20

Start date

2021-06-23

Completion date

Unknown

Last updated

2022-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Placebo group:150mg placebo + 200mg placebo

Pregabalin group:150mg pregabalin + 200mg placebo

Celecoxib group:150mg placebo + 200mg celecoxib

Combination therapy group:150mg pregabalin + 200mg celecoxib

Eligibility

Sex/Gender

All

Age

45 Years to 75 Years

Inclusion criteria

Inclusion criteria: Patients undergoing elective, primary, unilateral total knee arthroplasty.

Exclusion criteria

Exclusion criteria: 1. Patients with an ASA physical condition class of 4 or higher by the American Society of Anesthesiologists. 2. Patients with liver and kidney insufficiency, severe cardiopulmonary disease, severe digestive tract disease, and history of mental illness. 3. Patients who are allergic to celecoxib and pregabalin and allergic to anesthetics. 4. Patients who have taken celecoxib and pregabalin within 2 weeks before surgery. 5. Patients with cognitive impairment. 6. Patients who are unwilling to participate in this study.

Design outcomes

Primary

Measure	Time frame
Visual pain score;Cumulative dose of opioids;	—

Countries

China

Contacts

Public ContactXiang Bingyan

The Third Affiliated Hospital of Zunyi Medical University

xby1978@126.com+86 18685239990

Outcome results